OXBDF News and Press, Oxford BioMedica From 04/20/22

Oxford Biomedica Plc (OXBDF) Q4 2021 Earnings Conference Call April 20, 2022, 8:00 AM ET Company Participants Dr. Roch Doliveux – Chairman, Interim Chief Executive Officer Sophia Bolhassan – Director of Investor Relations Kyri Mitrophanous – Chief Scientific Officer Stuar...

Oxford Biomedica (OTCPK:OXBDF) released Wednesday its FY21 preliminary results with revenue of £142.8M (+63% Y/Y). Revenues from bioprocessing and commercial development rose 87% linked to the commercial manufacturing of the adenovirus-based Oxford AstraZeneca CO...

Oxford Biomedica (OTCPK:OXBDF) completed its deal with Homology Medicines (NASDAQ:FIXX) to establish its first U.S.-based subsidiary Oxford Biomedica Solutions, an Adeno-Associated Virus (AAV) manufacturing and innovation business. Under the deal, which was announced in January, ...

Oxford Biomedica plc (OXBDF) Q2 2021 Earnings Conference Call September 22, 2021 8:00 A.M. ET Company Participants Sophia Bolhassan - Director of Investor Relations John Dawson - Chief Executive Officer Kyri Mitrophanous - Chief Scientific Officer Stuart Paynter - Chief Financial Officer Conf...

The following slide deck was published by Oxford Biomedica plc in conjunction with their 2021 Q2 earnings call. For further details see: Oxford Biomedica plc 2021 Q2 - Results - Earnings Call Presentation

Oxford Biomedica (OXBDF) upgrades financial guidance for supply agreement with AstraZeneca (AZN) for manufacturing of COVID-19 vaccine.The company is raising its guidance for revenues from AstraZeneca to be in excess of £100M from £50M, and as a result expects significant growth in ...

The following slide deck was published by Oxford Biomedica plc in conjunction with their 2020 Q4 earnings call. For further details see: Oxford Biomedica plc 2020 Q4 - Results - Earnings Call Presentation

Oxford Biomedica plc (OXBDF) Q4 2020 Earnings Conference Call April 15, 2021 08:00 ET Company Participants Catherine Isted - Head, Corporate Development and Investor Relations John Dawson - Chief Executive Officer Stuart Paynter - Chief Financial Officer Kyri Mitrophanous - Chief Scientific O...

Oxford Biomedica (OXBDF) reported prelim total revenues of £87.7M (+37% Y/Y) for the year ended Dec.31, 2020.Operating EBITDA profit of £7.3M (2019: £5.2M loss), marginally above guided range; operating loss incurred of £5.7 million (2019: £14.5M loss).Cash of £4...

SIOX has promising results in its gene therapy programs. Not only is the Parkinson's disease program showing impressive results, but recent developments on the rare disease front are also very encouraging. I work through these developments and then turn to the company's valuation ...